Contributors
Latest:
Study Shows Zejula's Benefit in Treating Ovarian CancerSuperior progression-free survival (PFS) was seen in patients with ovarian cancer who previously had a partial response (PR) to platinum-based therapy when they took Zejula (niraparib). This response was seen in patients with or without germline BRCA mutations, according to data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.
Latest:
An Oncology Nurse at HeartThis essay was written by her colleagues, Jeanine Gordon and Jaclyn Andronico, Memorial Sloan Kettering Cancer Center, nominating Lisa Klempner, M.S.N., RN, OCN for CURE®’s 2019 Extraordinary Healer® Award.
Latest:
Filling the Medication GapIt can be challenging and confusing to get prescription drugs paid for in Canada. Drug access navigators can help.
Latest:
A Personal Journey: Improving the Lives of People With Lung CancerIt's been 17 years since my diagnosis of stage 3a non–small cell lung cancer. I can remember that moment as if it was yesterday.
Latest:
Finding a New Friend Through CancerAn Extraordinary Healer essay honoring Debbie O’Sullivan, RN, OCN [UT Health Northeast Cancer Treatment and Prevention Center in Tyler, Texas]
Latest:
What to Expect When Going on a PARP Inhibitor for Ovarian CancerChemotherapy and PARP inhibitors may share some side effects, but there are some major differences between the two when it comes to treating ovarian cancer.
Latest:
What to Do When a Friend Gets CancerA prostate cancer survivor offers his thoughts on what you should (and shouldn't) say to someone who was recently diagnosed.
Latest:
Helping Patients Fight Cancer With All Her Heart and SoulAn essay honoring SARA SARGENTE, RN, OCN [ORANGE REGIONAL MEDICAL CENTER, MIDDLETOWN, NEW YORK]
Latest:
Let's Talk About Cancer Prevention and the Power of Support"I don’t have cancer, but here I am. This is my life. This is my reality. I am BRCA positive."
Latest:
Long-Term Data Show Optune Offers a Survival Benefit in GlioblastomaLong-term data from the phase 3 EF-14 study showed that Optune plus temozolomide had a survival benefit compared to temozolomide alone.
Latest:
Survivors and HealersI didn’t like thinking of myself as a “survivor.” There was something … I don’t know. Something a little shameful, maybe, about it.
Latest:
Uncertain ObligationsNavigating the emotional and practical hurdles of caring for parents and stepparents.
Latest:
Good Karma From My Oncology Nurse, a Kindred SpiritAn Extraordinary Healer essay honoring Sharon Bird, BSN, RN [ THOMAS JEFFERSON UNIVERSITY HOSPITAL IN RADNOR, PENNSYLVANIA ]
Latest:
MSI Testing Is Crucial in Colorectal CancerGenetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.
Latest:
Discussing PARP Inhibitors in Triple-Negative Breast CancerAs the treatment paradigm shifts for triple-negative breast cancer, PARP inhibitors will continue to play a role.
